Traws Pharma, Inc. (ONTX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Traws Pharma, Inc.

Catalyst Biosciences, Inc.

Applied DNA Sciences, Inc.

Elutia, Inc.

22nd Century Group, Inc.

Microbot Medical, Inc.

NeuroBo Pharmaceuticals, Inc.

BiomX, Inc.

Orgenesis, Inc.

AquaBounty Technologies, Inc.

Vascular Biogenics Ltd.

Why is Traws Pharma, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of 29.91% over the last 5 years

Positive results in Jun 25

NET SALES(HY) At USD 2.79 MM has Grown at 2,369.03%
ROCE(HY) Highest at 1,224.29%
RAW MATERIAL COST(Y) Fallen by -7.59% (YoY)

With ROE of 939.05%, it has a does not qualify valuation with a 1.53 Price to Book Value

Over the past year, while the stock has generated a return of -41.03%, its profits have risen by 410.2%

High Institutional Holdings at 48.49%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 15.66% over the previous quarter.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -41.03% returns

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Traws Pharma, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Traws Pharma, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Traws Pharma, Inc.

-54.44%

-0.44

189.94%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

29.91%

EBIT Growth (5y)

-39.55%

EBIT to Interest (avg)

-21.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.66

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

48.49%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.53

EV to EBIT

0.14

EV to EBITDA

0.14

EV to Capital Employed

0.68

EV to Sales

-6.76

PEG Ratio

Dividend Yield

ROCE (Latest)

496.52%

ROE (Latest)

939.05%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company

NET SALES(HY)

At USD 2.79 MM has Grown at 2,369.03%

ROCE(HY)

Highest at 1,224.29%

RAW MATERIAL COST(Y)

Fallen by -7.59% (YoY

OPERATING PROFIT(Q)

Highest at USD -1.25 MM

PRE-TAX PROFIT(Q)

Highest at USD -1.06 MM

NET PROFIT(Q)

At USD -0.77 MM has Grown at 86.42%

-4What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -26.94 MM

CASH AND EQV(HY)

Lowest at USD 29.02 MM

Here's what is working for Traws Pharma, Inc.

Net Sales

At USD 2.79 MM has Grown at 2,369.03%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Operating Profit

Highest at USD -1.25 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -1.06 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit

At USD -1.06 MM has Grown at 81.32%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -0.77 MM has Grown at 86.42%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost

Fallen by -7.59% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Traws Pharma, Inc.

Operating Cash Flow

Lowest at USD -26.94 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv

Lowest at USD 29.02 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents